Fig. 7From: Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysisForest plot of studies that compared (A) major bleeding in patients treated with rivaroxaban, (B) clinically relevant nonmajor bleeding (CRNMB) in patients treated with rivaroxaban, (C) recurrent VTE in patients treated with rivaroxaban, and (D) major bleeding in patients treated with apixaban in the DOAC and LMWH groupsBack to article page